BACKGROUND:Troponin is the preferred biomarker for risk stratification in non-ST elevation ACS. The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined. METHODS:Troponin T (TnT) was measured in 1,250 patients at presentation undergoing fibrinolysis for STEMI in CLARITY-TIMI 28. ST-segment resolution was measured at 90 minutes. Multivariable logistic regression was used to examine the independent association between TnT levels, STRes, and 30-day cardiovascular (CV) mortality. RESULTS: Patients were classified into undetectable TnT at baseline (n = 594), detectable but below the median of 0.12 ng/mL (n = 330), and above the median (n = 326). Rates of 30-day CV death were 1.5%, 4.5%, and 9.5%, respectively (P < .0001). Compared with those with undetectable levels and adjusting for baseline factors, the odds ratios for 30-day CV death were 4.56 (1.72-12.08, P = .002) and 5.81 (2.29-14.73, P = .0002) for those below and above the median, respectively. When combined with STRes, there was a significant gradient of risk, and in a multivariable model both baseline TnT (P = .004) and STRes (P = .003) were significant predictors of 30-day CV death. The addition of TnT and STRes to clinical risk factors significantly improved the C-statistic (from 0.86 to 0.90, P = .02) and the integrated discriminative improvement (7.1% increase) (P = .0009). CONCLUSIONS: Baseline TnT and 90-minute STRes are independent predictors of 30-day CV death in patients with STEMI. Use of these 2 simple, readily available tools can aid clinicians in early risk stratification. Copyright 2010 Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: Troponin is the preferred biomarker for risk stratification in non-ST elevation ACS. The incremental prognostic use of the initial magnitude of troponin elevation and its value in conjunction with ST-segment resolution (STRes) in ST elevation myocardial infarction (STEMI) is less well defined. METHODS:Troponin T (TnT) was measured in 1,250 patients at presentation undergoing fibrinolysis for STEMI in CLARITY-TIMI 28. ST-segment resolution was measured at 90 minutes. Multivariable logistic regression was used to examine the independent association between TnT levels, STRes, and 30-day cardiovascular (CV) mortality. RESULTS:Patients were classified into undetectable TnT at baseline (n = 594), detectable but below the median of 0.12 ng/mL (n = 330), and above the median (n = 326). Rates of 30-day CV death were 1.5%, 4.5%, and 9.5%, respectively (P < .0001). Compared with those with undetectable levels and adjusting for baseline factors, the odds ratios for 30-day CV death were 4.56 (1.72-12.08, P = .002) and 5.81 (2.29-14.73, P = .0002) for those below and above the median, respectively. When combined with STRes, there was a significant gradient of risk, and in a multivariable model both baseline TnT (P = .004) and STRes (P = .003) were significant predictors of 30-day CV death. The addition of TnT and STRes to clinical risk factors significantly improved the C-statistic (from 0.86 to 0.90, P = .02) and the integrated discriminative improvement (7.1% increase) (P = .0009). CONCLUSIONS: Baseline TnT and 90-minute STRes are independent predictors of 30-day CV death in patients with STEMI. Use of these 2 simple, readily available tools can aid clinicians in early risk stratification. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Wei-Ching Chang; Eric Boersma; Christopher B Granger; Robert A Harrington; Robert M Califf; Maarten L Simoons; Neal S Kleiman; Paul W Armstrong Journal: Am Heart J Date: 2004-07 Impact factor: 4.749
Authors: D A Morrow; C P Cannon; N Rifai; M J Frey; R Vicari; N Lakkis; D H Robertson; D A Hille; P T DeLucca; P M DiBattiste; L A Demopoulos; W S Weintraub; E Braunwald Journal: JAMA Date: 2001-11-21 Impact factor: 56.272
Authors: E M Ohman; P W Armstrong; H D White; C B Granger; R G Wilcox; W D Weaver; W B Gibler; A L Stebbins; C Cianciolo; R M Califf; E J Topol Journal: Am J Cardiol Date: 1999-12-01 Impact factor: 2.778
Authors: E Giannitsis; M Müller-Bardorff; S Lehrke; U Wiegand; R Tölg; B Weidtmann; F Hartmann; G Richardt; H A Katus Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: D A Morrow; E M Antman; A Charlesworth; R Cairns; S A Murphy; J A de Lemos; R P Giugliano; C H McCabe; E Braunwald Journal: Circulation Date: 2000-10-24 Impact factor: 29.690
Authors: Erik Björklund; Bertil Lindahl; Per Johanson; Tomas Jernberg; Ann Marie Svensson; Per Venge; Lars Wallentin; Mikael Dellborg Journal: Eur Heart J Date: 2004-01 Impact factor: 29.983
Authors: R David Anderson; Harvey D White; E Magnus Ohman; Galen S Wagner; Mitchell W Krucoff; Paul W Armstrong; W Douglas Weaver; W Brian Gibler; Amanda L Stebbins; Robert M Califf; Eric J Topol Journal: Am Heart J Date: 2002-07 Impact factor: 4.749
Authors: Christopher E Buller; Yuling Fu; Kenneth W Mahaffey; Thomas G Todaro; Peter Adams; Cynthia M Westerhout; Harvey D White; Arnoud W J van 't Hof; Frans J Van de Werf; Galen S Wagner; Christopher B Granger; Paul W Armstrong Journal: Circulation Date: 2008-09-08 Impact factor: 29.690